Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433286 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL11664515 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTMDM4LMNAMDM2 | |
| SCHEMBL14915930 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2MAPTMDM4LMNAMDM2 | |
| SCHEMBL434126 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL732002 | 0.76 | ATM (0.50) | SMN1; SMN2MAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL28510565 | 0.75 | SMN1; SMN2 (0.61) | SMN1; SMN2MAPTMDM4LMNAMDM2 | |
| SCHEMBL21798477 | 0.74 | TDP1 (0.46) | SMN1; SMN2MAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL11672524 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTMDM4LMNAMDM2 | |
| SCHEMBL11841853 | 0.73 | SMN1; SMN2 (0.62) | SMN1; SMN2MAPTMDM4LMNAMDM2 | |
| SCHEMBL24661545 | 0.70 | SMN1; SMN2 (0.62) | SMN1; SMN2MAPTMDM4LMNAMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595994-B1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| US-8759523-B2 | Process for preparing pyrano—[2,3-C]pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| EP-2595994-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | Glaxo Group Limited (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | GLAXO GROUP LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2012012391-A2 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116436-A1 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES | DHPS, AKR1C3, Q6ZSR9 | SMN1; SMN2 4213/4885MAPT 4395/4885MDM4 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.